Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals

The impact of rapid weight lose through caloric restriction

Antonios M. Xydakis, Christopher C. Case, Peter H. Jones, Ron C. Hoogeveen, Mine-Yine Liu, E. O'Brian Smith, Kathleen W. Nelson, Christie M. Ballantyne

Research output: Contribution to journalArticle

228 Citations (Scopus)

Abstract

Severe obesity increases the prevalence of the metabolic syndrome, and moderate acute weight loss with a very low-calorie diet in obese subjects with the metabolic syndrome leads to significant metabolic benefits. Adiponectin has been implicated in both the pathogenesis of obesity-related insulin resistance and increased inflammation. We analyzed the relationship of the adipocyte-derived hormone adiponectin with indices of inflammation, adiposity, and insulin resistance in obese subjects with (MS+, n = 40) and without (MS-, n = 40) the metabolic syndrome and examined the acute effects of rapid weight loss. MS+ subjects had significantly lower adiponectin (7.6 ± 0.6 vs. 10.4 ± 0.6 μg/ml; P = 0.003) and significantly higher TNF-α (3.3 ± 0.2 vs. 2.8 ± 0.3 pg/ml; P = 0.004) levels compared with MS- subjects matched for age and body mass index. Plasma adiponectin and TNF-α levels were inversely related to the number of metabolic syndrome factors in a stepwise manner. After 4-6 wk of weight loss, there was marked improvement in glucose, insulin, leptin, and triglycerides, whereas adiponectin and TNF-α concentrations did not change. Thus, increases in plasma levels of adiponectin or reductions in TNF-α are not required for marked improvements in glucose/insulin and lipid metabolism with acute weight loss.

Original languageEnglish
Pages (from-to)2697-2703
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume89
Issue number6
DOIs
Publication statusPublished - 2004 Jun 1

Fingerprint

Caloric Restriction
Adiponectin
Inflammation
Weights and Measures
Weight Loss
Insulin
Insulin Resistance
Plasmas
Glucose
Morbid Obesity
Adiposity
Leptin
Lipid Metabolism
Adipocytes
Triglycerides
Body Mass Index
Obesity
Hormones

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Xydakis, Antonios M. ; Case, Christopher C. ; Jones, Peter H. ; Hoogeveen, Ron C. ; Liu, Mine-Yine ; O'Brian Smith, E. ; Nelson, Kathleen W. ; Ballantyne, Christie M. / Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals : The impact of rapid weight lose through caloric restriction. In: Journal of Clinical Endocrinology and Metabolism. 2004 ; Vol. 89, No. 6. pp. 2697-2703.
@article{a053a845027c48609cfb5c276a88305b,
title = "Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: The impact of rapid weight lose through caloric restriction",
abstract = "Severe obesity increases the prevalence of the metabolic syndrome, and moderate acute weight loss with a very low-calorie diet in obese subjects with the metabolic syndrome leads to significant metabolic benefits. Adiponectin has been implicated in both the pathogenesis of obesity-related insulin resistance and increased inflammation. We analyzed the relationship of the adipocyte-derived hormone adiponectin with indices of inflammation, adiposity, and insulin resistance in obese subjects with (MS+, n = 40) and without (MS-, n = 40) the metabolic syndrome and examined the acute effects of rapid weight loss. MS+ subjects had significantly lower adiponectin (7.6 ± 0.6 vs. 10.4 ± 0.6 μg/ml; P = 0.003) and significantly higher TNF-α (3.3 ± 0.2 vs. 2.8 ± 0.3 pg/ml; P = 0.004) levels compared with MS- subjects matched for age and body mass index. Plasma adiponectin and TNF-α levels were inversely related to the number of metabolic syndrome factors in a stepwise manner. After 4-6 wk of weight loss, there was marked improvement in glucose, insulin, leptin, and triglycerides, whereas adiponectin and TNF-α concentrations did not change. Thus, increases in plasma levels of adiponectin or reductions in TNF-α are not required for marked improvements in glucose/insulin and lipid metabolism with acute weight loss.",
author = "Xydakis, {Antonios M.} and Case, {Christopher C.} and Jones, {Peter H.} and Hoogeveen, {Ron C.} and Mine-Yine Liu and {O'Brian Smith}, E. and Nelson, {Kathleen W.} and Ballantyne, {Christie M.}",
year = "2004",
month = "6",
day = "1",
doi = "10.1210/jc.2003-031826",
language = "English",
volume = "89",
pages = "2697--2703",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals : The impact of rapid weight lose through caloric restriction. / Xydakis, Antonios M.; Case, Christopher C.; Jones, Peter H.; Hoogeveen, Ron C.; Liu, Mine-Yine; O'Brian Smith, E.; Nelson, Kathleen W.; Ballantyne, Christie M.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 89, No. 6, 01.06.2004, p. 2697-2703.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals

T2 - The impact of rapid weight lose through caloric restriction

AU - Xydakis, Antonios M.

AU - Case, Christopher C.

AU - Jones, Peter H.

AU - Hoogeveen, Ron C.

AU - Liu, Mine-Yine

AU - O'Brian Smith, E.

AU - Nelson, Kathleen W.

AU - Ballantyne, Christie M.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Severe obesity increases the prevalence of the metabolic syndrome, and moderate acute weight loss with a very low-calorie diet in obese subjects with the metabolic syndrome leads to significant metabolic benefits. Adiponectin has been implicated in both the pathogenesis of obesity-related insulin resistance and increased inflammation. We analyzed the relationship of the adipocyte-derived hormone adiponectin with indices of inflammation, adiposity, and insulin resistance in obese subjects with (MS+, n = 40) and without (MS-, n = 40) the metabolic syndrome and examined the acute effects of rapid weight loss. MS+ subjects had significantly lower adiponectin (7.6 ± 0.6 vs. 10.4 ± 0.6 μg/ml; P = 0.003) and significantly higher TNF-α (3.3 ± 0.2 vs. 2.8 ± 0.3 pg/ml; P = 0.004) levels compared with MS- subjects matched for age and body mass index. Plasma adiponectin and TNF-α levels were inversely related to the number of metabolic syndrome factors in a stepwise manner. After 4-6 wk of weight loss, there was marked improvement in glucose, insulin, leptin, and triglycerides, whereas adiponectin and TNF-α concentrations did not change. Thus, increases in plasma levels of adiponectin or reductions in TNF-α are not required for marked improvements in glucose/insulin and lipid metabolism with acute weight loss.

AB - Severe obesity increases the prevalence of the metabolic syndrome, and moderate acute weight loss with a very low-calorie diet in obese subjects with the metabolic syndrome leads to significant metabolic benefits. Adiponectin has been implicated in both the pathogenesis of obesity-related insulin resistance and increased inflammation. We analyzed the relationship of the adipocyte-derived hormone adiponectin with indices of inflammation, adiposity, and insulin resistance in obese subjects with (MS+, n = 40) and without (MS-, n = 40) the metabolic syndrome and examined the acute effects of rapid weight loss. MS+ subjects had significantly lower adiponectin (7.6 ± 0.6 vs. 10.4 ± 0.6 μg/ml; P = 0.003) and significantly higher TNF-α (3.3 ± 0.2 vs. 2.8 ± 0.3 pg/ml; P = 0.004) levels compared with MS- subjects matched for age and body mass index. Plasma adiponectin and TNF-α levels were inversely related to the number of metabolic syndrome factors in a stepwise manner. After 4-6 wk of weight loss, there was marked improvement in glucose, insulin, leptin, and triglycerides, whereas adiponectin and TNF-α concentrations did not change. Thus, increases in plasma levels of adiponectin or reductions in TNF-α are not required for marked improvements in glucose/insulin and lipid metabolism with acute weight loss.

UR - http://www.scopus.com/inward/record.url?scp=2942677231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942677231&partnerID=8YFLogxK

U2 - 10.1210/jc.2003-031826

DO - 10.1210/jc.2003-031826

M3 - Article

VL - 89

SP - 2697

EP - 2703

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -